ID: ALA567136

Max Phase: Preclinical

Molecular Formula: C12H13NaO6S

Molecular Weight: 286.31

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C([O-])[C@]1(O)C=C(OCc2cccs2)[C@@H](O)[C@H](O)C1.[Na+]

Standard InChI:  InChI=1S/C12H14O6S.Na/c13-8-4-12(17,11(15)16)5-9(10(8)14)18-6-7-2-1-3-19-7;/h1-3,5,8,10,13-14,17H,4,6H2,(H,15,16);/q;+1/p-1/t8-,10+,12-;/m1./s1

Standard InChI Key:  OVZJTVHISXYBNE-RBJCUBAZSA-M

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 286.31

Molecular Weight (Monoisotopic): 286.0511

AlogP: 0.09

#Rotatable Bonds: 4

Polar Surface Area: 107.22

Molecular Species: ACID

HBA: 6

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.91

CX Basic pKa:

CX LogP: -0.52

CX LogD: -3.73

Aromatic Rings: 1

Heavy Atoms: 19

QED Weighted: 0.62

Np Likeness Score: 0.16

References

1. Prazeres VF, Tizón L, Otero JM, Guardado-Calvo P, Llamas-Saiz AL, van Raaij MJ, Castedo L, Lamb H, Hawkins AR, González-Bello C..  (2010)  Synthesis and biological evaluation of new nanomolar competitive inhibitors of Helicobacter pylori type II dehydroquinase. Structural details of the role of the aromatic moieties with essential residues.,  53  (1): [PMID:19911771] [10.1021/jm9010466]

2. Tizón L, Otero JM, Prazeres VF, Llamas-Saiz AL, Fox GC, van Raaij MJ, Lamb H, Hawkins AR, Ainsa JA, Castedo L, González-Bello C..  (2011)  A prodrug approach for improving antituberculosis activity of potent Mycobacterium tuberculosis type II dehydroquinase inhibitors.,  54  (17): [PMID:21780742] [10.1021/jm2006063]

Source

Source(1):

• Scientific Literature